High-throughput microfluidic small whole-organism screening system is constructed based on multiple cross-disciplinary science and technology areas including pharmacology, toxicology and microfluidics. The system enables the establishment and streamline of several important in vivo models for human diseases as well as new drug discovery and pharmacokinetic screening assays, fully utilizing zebrafish as a model with its genetic and physiological similarities with human. The platform combines microfluidic chip technology and multi-modal high-throughput screening into an integrated high-technology unit, providing a new, effective, and efficient method for drug discovery, cross-bridging technology with biology. Based on the system, our research team further invented a patented zebrafish model for vascular insufficiency disorders and other useful zebrafish models for human diseases such as cerebral hemorrhage, osteoporosis, and Parkinson's disease. We have employed this system to evaluate the safety of natural products and traditional Chinese medicine, and successfully discovered several potential therapeutic compounds for the regulation of angiogenesis and neuroprotection. Achievements from this project includes international and national patents and high-impact highly cited journal articles, making a significant contribution to the development of science and technology in Macau. 

Fig 1 Our research team further invented a patented zebrafish model for vascular insufficiency disorders and other useful zebrafish models for human diseases such as cerebral hemorrhage, osteoporosis, and Parkinson's disease.

Fig 2 The platform combines microfluidic chip technology and multi-modal high-throughput screening into an integrated high-technology unit, providing a new, effective, and efficient method for drug discovery, cross-bridging technology with biology.